No article in the knowledge graph for Mammotome yet.
Who is Mammotome?
Mammotome is a medical device company that develops and supplies breast biopsy and localization systems for image-guided breast cancer diagnosis and surgical planning.
- Vacuum-assisted breast biopsy systems for image-guided tissue sampling in radiology and breast centers.
- Breast lesion localization technologies to support surgical excision planning and guidance.
- Integrated biopsy and localization accessories, including needles, markers, and procedure consumables.
- Education and training resources for clinicians using image-guided breast biopsy and localization systems.
- Collaboration with hospitals, imaging centers, and breast care programs for standardized breast care pathways.
Show more
More About Mammotome
Mammotome develops minimally invasive breast biopsy and localization solutions used in hospitals, breast imaging centers, and surgical practices as part of breast cancer diagnostic and treatment workflows. Its systems are designed to work within multimodality imaging environments, including ultrasound, stereotactic X-ray, and MRI-guided procedures, enabling radiologists and surgeons to obtain targeted tissue samples and accurately localize lesions prior to surgery.
The company’s vacuum-assisted biopsy platforms (breast biopsy devices) support percutaneous tissue sampling through small incisions, which can reduce the need for open surgical biopsies in diagnostic pathways. These systems are typically integrated with imaging guidance hardware and software already deployed in enterprise radiology environments, and they are compatible with existing picture archiving and communication systems (PACS) and radiology information systems (RIS) workflows through standard imaging protocols used by the host imaging equipment.
Mammotome also provides breast lesion localization solutions (surgical localization devices) that enable clinicians to mark lesion sites before operative procedures. These products are designed to align with surgical oncology workflows, allowing surgeons to identify and excise target tissue with support from intraoperative imaging or palpation, depending on the selected localization approach. Marker placement and localization data become part of the broader patient record, connecting radiology, pathology, and surgery teams.
From an enterprise perspective, Mammotome’s offerings System Integration Testing (SIT) within the breast health and interventional radiology device stack rather than the IT software stack. Procurement and integration decisions often involve radiology service lines, perioperative services, and supply chain teams, with attention to compatibility with existing imaging systems, procedure room layouts, and sterilization or reprocessing protocols. The company’s consumables and accessories are incorporated into ongoing supply contracts and inventory management systems alongside other interventional radiology and surgical products.
In marketplace and directory taxonomies, Mammotome aligns with categories such as breast biopsy systems, image-guided interventional devices, and breast lesion localization solutions. Its portfolio is used in conjunction with imaging platforms from modality vendors, pathology services for tissue analysis, and electronic medical record systems that document procedure details and diagnostic outcomes. The combination of devices, markers, and procedure tools supports standardized workflows across diagnostic assessment, pre-surgical planning, and follow-up imaging in breast care programs.
Our description of Mammotome. Updated December 2025.
